Patriarca P A, Schlech W F, Hinman A R, Conn J M, Gunn W J
Public Health Rep. 1982 Sep-Oct;97(5):406-8.
It is estimated that less than 10 percent of patients thought to be at high risk of invasive pneumococcal diseases have received 14-valent pneumococcal polysaccharide vaccine. To determine if any of these groups are more likely to be vaccinated than others, 893 private, primary-care physicians were surveyed nationwide. Although there was general agreement that the vaccine is indicated for the high-risk groups, patients with cardiorespiratory diseases were the only ones usually immunized by more than half of the survey respondents. The discrepancy between attitudes and practices could not be attributed to any specific factor.
据估计,被认为有侵袭性肺炎球菌疾病高风险的患者中,接受14价肺炎球菌多糖疫苗接种的不到10%。为了确定这些群体中是否有任何一组比其他组更有可能接种疫苗,在全国范围内对893名私人初级保健医生进行了调查。尽管普遍认为该疫苗适用于高风险群体,但只有患有心肺疾病的患者通常会被超过一半的受访者进行免疫接种。态度和做法之间的差异无法归因于任何特定因素。